enGene Holdings Inc. (NASDAQ:ENGN) Receives $11.05 Average Price Target from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been assigned a consensus rating of “Hold” from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $11.0455.

Several research analysts have recently weighed in on ENGN shares. HC Wainwright lowered their target price on enGene from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Guggenheim cut enGene from a “buy” rating to a “neutral” rating in a report on Thursday, May 7th. UBS Group reduced their price objective on enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Citizens Jmp lowered enGene from an “outperform” rating to a “market perform” rating in a research note on Friday, May 8th. Finally, Leerink Partners cut enGene from an “outperform” rating to a “market perform” rating and set a $2.00 target price for the company. in a report on Friday, May 8th.

enGene Stock Up 3.3%

Shares of ENGN stock opened at $1.87 on Friday. enGene has a twelve month low of $1.40 and a twelve month high of $12.25. The stock has a market cap of $125.27 million, a P/E ratio of -0.86 and a beta of -0.28. The stock has a 50 day moving average of $1.80 and a 200 day moving average of $4.61. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, June 15th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. During the same quarter last year, the company posted $0.51 earnings per share. As a group, sell-side analysts expect that enGene will post -1.84 EPS for the current year.

Institutional Trading of enGene

Several hedge funds have recently made changes to their positions in ENGN. SR One Capital Management LP acquired a new position in enGene in the second quarter valued at approximately $1,293,607,000. Eversept Partners LP increased its stake in enGene by 12.0% during the first quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock worth $3,477,000 after acquiring an additional 54,708 shares during the last quarter. Renaissance Technologies LLC raised its position in enGene by 651.1% in the first quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock valued at $1,063,000 after purchasing an additional 135,318 shares during the period. Siren L.L.C. raised its position in enGene by 57.5% in the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after purchasing an additional 1,916,895 shares during the period. Finally, Sei Investments Co. acquired a new position in shares of enGene in the 1st quarter valued at $409,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.